TrialAmerican journal of hematology2020

Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.

Brian G M Durie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.